Validation of the VIRADIA App for Neurological and Cognitive Diagnostics in Virtual Reality

The VIRADIA validation study investigates the psychometric properties-validity and reliability-of a Virtual Reality (VR) diagnostic platform designed for neurological and cognitive assessment. The platform includes VR adaptations of nine established clinical tests commonly used in neurology and neuropsychology. These tests evaluate fine motor coordination, gait and balance, processing speed, attention, and executive functioning.

The study follows an observational, within-subjects, paired design. Each participant completes both the standard (paper-based or face-to-face) version and the corresponding VR version of all tests. The order of modalities is counterbalanced across participants to control for order effects. Two groups are enrolled:

• Healthy adults (control group)
• Patients with neurological conditions (clinical group; one priority diagnosis in the first phase)

Objectives

• To evaluate the convergent validity of VR-based test scores compared to standard clinical versions.
• To analyze discriminative validity, i.e., whether VR test results can differentiate between healthy individuals and neurological patients comparably to standard methods.

Procedures

After informed consent, demographic and clinical data (age, gender, education, diagnosis, medication) are recorded. Participants complete all tests under both conditions (standard and VR). After testing, participants fill out a short questionnaire on VR tolerability and subjective experience.

Data Collection and Sample Size

The study aims to include 200 participants (100 healthy, 100 patients). The target sample size was determined using a priori power analysis for paired ROC/AUC comparisons (AUC ≥ 0.75, ΔAUC ≤ 0.05, α = 0.05, power = 0.90), with an additional 15% margin for attrition.

Statistical Analyses

• Convergent validity: Pearson/Spearman correlations (95% CI) between VR and standard scores.
• Agreement: Paired t-tests/Wilcoxon tests and Bland-Altman plots (bias, 95% limits of agreement).
• Discriminative validity: ROC/AUC analysis comparing patients and healthy participants.
• Reliability: Intraclass Correlation Coefficient (ICC[2,1]) for the test-retest subsample.

Ethical Considerations

The study is non-invasive and presents minimal risk. No experimental drug, device, or biological material is used. All participants provide informed consent prior to participation. The study has been approved by the Ethics Committee of the Nitra Self-Governing Region (Approval No. 09I05-03-804).

Expected Outcomes

The study will produce empirical evidence supporting the validity, reliability, and clinical utility of the VIRADIA platform. This validation will enable the integration of standardized VR-based diagnostics into neurological practice and contribute to early detection of neurodegenerative disorders in both clinical and home settings.

Inclusion criteria

• Age 18-80 years.
• Ability to provide informed consent.
• Adequate vision and hearing to complete testing.
• For the neurological group: confirmed diagnosis of a neurological disorder (e.g., Parkinson's disease, multiple sclerosis, or similar).
• For the control group: no history of neurological or psychiatric disease.

Exclusion criteria

• Severe cognitive impairment (MMSE < 24 or equivalent clinical judgment).
• Acute neurological or psychiatric condition interfering with testing.
• Severe motor disability preventing task performance (e.g., inability to use VR controller).
• Current substance abuse.
• Uncorrected visual impairment or vestibular disorder leading to intolerance of VR.